News
OncoBeta receives ethics approval for EPIC-Skin study to evaluate Rhenium-SCT in Australia
21st December 2021
Garching b. Munich, Germany – OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies…
OncoBeta launches International Registry for Non-Melanoma Skin Cancer
23rd November 2021
Garching near Munich, Germany – OncoBeta® GmbH announces the launch of a first-of-its- kind International Registry for NMSC.…
South African non-melanoma skin cancer patients now have greater access in the area of Johannesburg to innovative non-invasive treatment Rhenium-SCT®
Lethabong, South Africa, 16 November 2021: Today OncoBeta® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies…
First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Austria
Vienna, Austria, 28 October 2021: OncoBeta® GmbH, a medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma…
OncoBeta initiates international EPIC-Skin study with Rhenium-SCT® for the treatment of Skin Cancer
The multi-centre prospective study will evaluate the efficacy of the Rhenium-SCT® in non-melanoma skin cancer patients
Garching n. Munich, Germany–…
Australian Nuclear Science and Technology Organization (ANSTO), the new production partner of OncoBeta® GmbH in Australia
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia
New Non-Invasive Keloid Treatment using Rhenium-188 now available in South Africa
Province of Gauteng South Africa is first to offer an innovative single session keloid treatment without need of surgery
OncoBeta Announces Approval and ARTG Listing of Rhenium-SCT (Rhenium-188 paste) in Australia for the treatment of skin cancer lesions and skin tumors
Garching n. Munich, Germany, (December 18th, 2020) – OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device…
OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia
Innovative medical device Rhenium-SCT therapy for Non-Melanoma Skin Cancer to be produced in Australia
Group RPH and OncoBeta GmbH sign agreement for Sales Referral and Distribution of Rhenium-SCT® in Brazil.
Grupo RPH is now the Official Rhenium-SCT® Sales Representative and Distributor in Brazil for the treatment of Non-Melanoma Skin Cancer.